HuGE Literature Finder
Records 1-21
|
Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.
Genes, chromosomes & cancer 2020 May . VaNková Bohuslava, VanEcek Tomáš, Ptáková Nikola, Hájková Veronika, Dušek Martin, Michal Michael, Švajdler Peter, Daum OndRej, Daumová Magdaléna, Michal Michal, Mezencev Roman, Švajdler Mari |
|
Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer.
Molecular & cellular oncology 2020 7 (3): 1716618. Douglas Jason K, Callahan Rose E, Hothem Zachary A, Cousineau Craig S, Kawak Samer, Thibodeau Bryan J, Bergeron Shelli, Li Wei, Peeples Claire E, Wasvary Harry |
|
[Polymorphisms of mTORC1 genes and risk of primary colorectal adenocarcinoma in Chinese populations].
Zhonghua bing li xue za zhi = Chinese journal of pathology 2018 Jul 47 (7): 492-498. Yu L, Liu Z Y, Jiao J, Shi X L, Cui W L, Zhang W, Li Q |
|
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Cancer 2018 Jan . Ross Jeffrey S, Fakih Marwan, Ali Siraj M, Elvin Julia A, Schrock Alexa B, Suh James, Vergilio Jo-Anne, Ramkissoon Shakti, Severson Eric, Daniel Sugganth, Fabrizio David, Frampton Garrett, Sun James, Miller Vincent A, Stephens Philip J, Gay Laurie |
|
Tumor-biopsy stratification based on mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN.
Oncotarget 2017 Oct 8 (48): 84426-84433. Laes Jean-François, Sauvage Sebastien, Ghitti Grego |
|
Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia.
British journal of cancer 2017 Jun 117 (1): 136-143. Chakrabarty Sanjiban, Varghese Vinay Koshy, Sahu Pranoy, Jayaram Pradyumna, Shivakumar Bhadravathi M, Pai Cannanore Ganesh, Satyamoorthy Kapaet |
|
PI3K/Akt/mTOR signaling and plasma membrane proteins are implicated in responsiveness to adjuvant dendritic cell vaccination for metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Jul . Qian David C, Xiao Xiangjun, Byun Jinyoung, Suriawinata Arief A, Her Stephanie, Amos Christopher I, Barth Richa |
|
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.
Investigational new drugs 2015 Jun 33 (3): 720-8. Do Khanh, Speranza Giovanna, Bishop Rachel, Khin Sonny, Rubinstein Larry, Kinders Robert J, Datiles Manuel, Eugeni Michelle, Lam Michael H, Doyle L Austin, Doroshow James H, Kummar Shivaa |
|
Functional promoter rs2295080 T>G variant in MTOR gene is associated with risk of colorectal cancer in a Chinese population.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2015 Mar 70 28-32. Xu Ming, Gao Yan, Yu Tingting, Wang Jirong, Cheng Liang, Cheng Lifang, Cheng Dawei, Zhu Bao |
|
Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with colorectal cancer.
Annals of surgical oncology 2014 Dec 21 Suppl 4 S634-9. Lee Soo Jung, Kang Byung Woog, Chae Yee Soo, Kim Hye Jin, Park Su Yeon, Park Jun Seok, Choi Gyu Seog, Jeon Hyo-Sung, Lee Won Kee, Kim Jong Gwa |
|
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Acta oncologica (Stockholm, Sweden) 2014 Jul 53 (7): 852-64. Therkildsen Christina, Bergmann Troels K, Henrichsen-Schnack Tine, Ladelund Steen, Nilbert M |
|
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
PloS one 2014 9 (2): e89388. Jardim Denis L, Wheler Jennifer J, Hess Kenneth, Tsimberidou Apostolia M, Zinner Ralph, Janku Filip, Subbiah Vivek, Naing Aung, Piha-Paul Sarina A, Westin Shannon N, Roy-Chowdhuri Sinchita, Meric-Bernstam Funda, Hong David |
|
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Molecular cancer therapeutics 2013 Dec 12 (12): 2857-63. Ganesan Prasanth, Janku Filip, Naing Aung, Hong David S, Tsimberidou Apostolia M, Falchook Gerald S, Wheler Jennifer J, Piha-Paul Sarina A, Fu Siqing, Stepanek Vanda M, Lee J Jack, Luthra Rajyalakshmi, Overman Michael J, Kopetz E Scott, Wolff Robert A, Kurzrock Razel |
|
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.
Cancer medicine 2013 Jun 2 (3): 277-85. Price Timothy J, Hardingham Jennifer E, Lee Chee K, Townsend Amanda R, Wrin Joseph W, Wilson Kate, Weickhardt Andrew, Simes Robert J, Murone Carmel, Tebbutt Niall |
|
Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment.
Nutrition and cancer 2011 Nov 63 (8): 1226-34. Slattery Martha L, Lundgreen Abbie, Herrick Jennifer S, Caan Bette J, Potter John D, Wolff Roger |
|
Effect of nab-rapamycin versus rapamycin in colorectal cancer cell lines and associations with KRAS and PI3K mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): e13532. Kennecke H F, Rahman M, Yip S, Woods R, Schaeffer D, Tai |
|
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Molecular cancer therapeutics 2011 Mar 10 (3): 558-65. Janku Filip, Tsimberidou Apostolia M, Garrido-Laguna Ignacio, Wang Xuemei, Luthra Rajyalakshmi, Hong David S, Naing Aung, Falchook Gerald S, Moroney John W, Piha-Paul Sarina A, Wheler Jennifer J, Moulder Stacy L, Fu Siqing, Kurzrock Razel |
|
Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Feb 29 (4_suppl): 628. Lee S J, Kim J G, Chae Y S, Kang B W, Jeon S W, Park J S, Park J Y, Choi G S, Lee Y |
|
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
PloS one 2011 6 (7): e22769. Janku Filip, Lee J Jack, Tsimberidou Apostolia M, Hong David S, Naing Aung, Falchook Gerald S, Fu Siqing, Luthra Rajyalakshmi, Garrido-Laguna Ignacio, Kurzrock Razel |
|
Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Carcinogenesis 2010 Sep 31 (9): 1604-11. Slattery Martha L, Herrick Jennifer S, Lundgreen Abbie, Fitzpatrick Francis A, Curtin Karen, Wolff Roger |
|
Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
Oncology 2010 79 (3-4): 278-82. Kim Jong Gwang, Chae Yee Soo, Sohn Sang Kyun, Kang Byung Woog, Moon Joon Ho, Lee Soo Jung, Jeon Seong Woo, Park Jun Seok, Park Jin Young, Choi Gyu Se |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 15, 2021
- Content source: